Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy

Publisher： Karger

E-ISSN： 1423-0194|103|5|432-439

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.103, Iss.5, 2015-06, pp. : 432-439

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hematological Toxicity of Combined 177Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up

By  

Neuroendocrinology, Vol. 99, Iss. 2, 2014-04 ,pp. : 108-117

Karger

Access to resources Recommend Favorite

Treatment with the Radiolabelled Somatostatin Analog 177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

By  

Neuroendocrinology, Vol. 97, Iss. 4, 2013-05 ,pp. : 347-354

Karger

Access to resources Recommend Favorite

Treatment of Metastatic Neuroendocrine Tumors of the Thymus with Capecitabine and Temozolomide: A Case Series

By  

Neuroendocrinology, Vol. 97, Iss. 4, 2013-01 ,pp. : 318-321

Karger

Access to resources Recommend Favorite

Progesterone Receptor Isoforms A and B in Pancreatic Neuroendocrine Tumor

By  

Neuroendocrinology, Vol. 101, Iss. 4, 2015-03 ,pp. : 309-320

Karger

Access to resources Recommend Favorite

Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland

By  

Neuroendocrinology, Vol. 93, Iss. 3, 2011-02 ,pp. : 189-196

Karger

Access to resources Recommend Favorite